Literature DB >> 9473241

Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia.

U Consoli1, I El-Tounsi, A Sandoval, V Snell, H D Kleine, W Brown, J R Robinson, F DiRaimondo, W Plunkett, M Andreeff.   

Abstract

Fludarabine (F-ara-A), an adenine nucleoside analog with efficacy in B-cell chronic lymphocytic leukemia (B-CLL), has also been shown to have a long-lasting suppressive effect on T lymphocytes. In heterogeneous clinical samples, apoptosis cannot be detected by standard methods in small cellular subsets. We developed, therefore, a combined assay of in situ end-labeling of nicked DNA by terminal deoxynucleotide transferase, with measurements of cellular DNA content and surface antigens (CD3, CD4, CD8, and CD19) by multiparametric flow cytometry. This assay was used to determine F-ara-A-induced apoptosis in different lymphocyte subsets from CLL patients and normal controls treated with F-ara-A in vitro. Apoptosis was also correlated to bcl-2 protein levels. We observed a direct effect of F-ara-A on both B-CLL and T lymphocytes. The response to F-ara-A in B-CLL lymphocytes in vitro was Rai stage-dependent, the early-stages being more responsive (P = .01). Higher levels of spontaneous apoptosis were observed in B-CLL lymphocytes from early stage patients (P = .02). No difference was observed in spontaneous apoptosis of normal T cells in B-CLL, although T lymphocytes in late-stage disease were more sensitive to F-ara-A-induced apoptosis. Incubation with cyclosporin A did not affect B-CLL and T-lymphocyte survival compared with control cultures. Results suggested a direct apoptotic effect of F-ara-A on B-CLL lymphocytes that decreases with increasing clinical stage. No correlation was found between bcl-2 and spontaneous or F-ara-A-induced apoptosis. Apoptosis occurred at all cell-cycle stages and was not restricted to cells in S phase. The mechanisms of this stage-dependent apoptosis in CLL remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9473241

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.

Authors:  Folke Schriever; Dieter Huhn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Apoptosis in B-chronic lymphocytic leukaemia.

Authors:  L M Osorio; M Aguilar-Santelises
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

3.  A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.

Authors:  Meagan J Bemer; Mohamed Sorror; Brenda M Sandmaier; Paul V O'Donnell; Jeannine S McCune
Journal:  Cancer Chemother Pharmacol       Date:  2013-08-02       Impact factor: 3.333

4.  Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.

Authors:  Jeannine S McCune; Donald E Mager; Meagan J Bemer; Brenda M Sandmaier; Barry E Storer; Shelly Heimfeld
Journal:  Cancer Chemother Pharmacol       Date:  2015-05-17       Impact factor: 3.333

Review 5.  The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases.

Authors:  Michael Maris; Rainer Storb
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

6.  Selective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis.

Authors:  Jianguo Zhuang; Naomi Laing; Melanie Oates; Ke Lin; Gillian Johnson; Andrew R Pettitt
Journal:  Pharmacol Res Perspect       Date:  2014-09-01

7.  Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Authors:  Jurgen B Langenhorst; Thomas P C Dorlo; Erik M van Maarseveen; Stefan Nierkens; Jürgen Kuball; Jaap Jan Boelens; Charlotte van Kesteren; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

8.  Exercise Training and Natural Killer Cells in Cancer Survivors: Current Evidence and Research Gaps Based on a Systematic Review and Meta-analysis.

Authors:  Pedro L Valenzuela; Gonzalo Saco-Ledo; Alejandro Lucia; Carmen Fiuza-Luces; Alejandro Santos-Lozano; Javier S Morales; Adrián Castillo-García; Richard J Simpson
Journal:  Sports Med Open       Date:  2022-03-04

Review 9.  New insights into the synergism of nucleoside analogs with radiotherapy.

Authors:  Michael W Lee; William B Parker; Bo Xu
Journal:  Radiat Oncol       Date:  2013-09-26       Impact factor: 3.481

Review 10.  Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases.

Authors:  An R Van Rompay; Magnus Johansson; Anna Karlsson
Journal:  Pharmacol Ther       Date:  2003-11       Impact factor: 12.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.